STOCK TITAN

Exact Sciences to participate in J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Exact Sciences Corp. (Nasdaq: EXAS) will participate in the J.P. Morgan Healthcare Conference on January 8, 2024, at 2:15 p.m. ET, with a webcast available on the company's website.
Positive
  • None.
Negative
  • None.

MADISON, Wis., Jan. 2, 2024 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.

  • J.P. Morgan Healthcare Conference, San Francisco
    Presentation followed by Q&A on Monday, January 8, 2024 at 2:15 p.m. ET

The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com.

About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.

Contact:
Nathan Harrill
Exact Sciences Corp.
investorrelations@exactsciences.com
608-535-8659

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/exact-sciences-to-participate-in-jp-morgan-healthcare-conference-302024275.html

SOURCE Exact Sciences Corporation

Exact Sciences Corp. (Nasdaq: EXAS) will participate in the J.P. Morgan Healthcare Conference on January 8, 2024, at 2:15 p.m. ET.

The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com.
Exact Sciences Corp.

NASDAQ:EXAS

EXAS Rankings

EXAS Latest News

EXAS Stock Data

Diagnostic Imaging Centers
Health Care and Social Assistance
Link
Health Technology, Biotechnology
US
Madison

About EXAS

exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences'​ noninvasive colon cancer screening test, visit cologuardtest.com